CCS
NVRO

Crosspoint Capital Strategies’s NEVRO CORP. NVRO Stock Holding History

Crosspoint Capital Strategies’s Portfolio NVRO Stock Details NVRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-40,428
Closed -$4.22M – 184
2016
Q3 		$4.22M Buy
+40,428
New +$3.65M 5.71% 6

Other funds holding NVRO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Crosspoint Capital Strategies's NVRO Position: Q4 2016 in Review

Crosspoint Capital Strategies sold out of NEVRO CORP. (NVRO) in Q4 2016, closing a stake of 40,428 shares — an estimated $4.22M sold.

Crosspoint Capital Strategies first reported a position in NVRO in Q3 2016 and held it in 1 quarter. The position peaked at $4.22M in Q3 2016. 174 funds tracked by Wall St. Rank hold NVRO as of Q4 2016.

  • Crosspoint Capital Strategies reported no remaining NEVRO CORP. position as of Q4 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 40,428 NEVRO CORP. shares in Q4 2016, an estimated $4.22M.
  • Crosspoint Capital Strategies first reported a position in NEVRO CORP. in Q3 2016 and held it in 1 quarter.
  • Crosspoint Capital Strategies's NEVRO CORP. position peaked at $4.22M in Q3 2016.
  • 174 funds tracked by Wall St. Rank held NEVRO CORP. as of Q4 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2016, filed 23 Jan 2017.